The French Medicines Agency, ANSM, has warned that prolonged use of certain progestins such as promegestone (Surgestone 0.5 mg), medrogestone (Colprone 5 mg) and medroxyprogesterone acetate (Depo Provera 150 mg / 3 ml) increases the risk of meningioma.
These progestin-only medications are primarily intended for women and are used to treat a variety of health conditions, including female conditions such as endometriosis, infertility, and menopausal symptoms. They are sometimes also used as contraceptives but have been associated with the development of non-malignant brain tumors. Androcur, Lutéran, and Lutényl have also been linked to these meningiomas, while other progestins like Utrogestan, Duphaston, and Climaston appear to be safe. Progestogen-based intrauterine devices also pose no risks.
Uncertainty remains regarding Dienogest, which requires more studies to draw reliable statistical conclusions. This warning from the ANSM is perceived positively by patients who criticized the health authorities for being slow to react to the first warning signals concerning Androcur.
 Frank Verain
|
27/06/2023 | 
